Review of postmenopausal osteoporosis pharmacotherapy

Nutrition in Clinical Practice

Volumn 22, Issue 3, 2007, Pages 276-285

  Mayes, Stacey L ^a  

^a WOLFSON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; BISPHOSPHONIC ACID DERIVATIVE; CALCI CHEW; CALCIUM; CALCIUM CARBONATE; CALCIUM GLUBIONATE; CALCIUM LACTATE; CITRATE CALCIUM; CITRATE POTASSIUM; CITRICAL; CLODRONIC ACID; COLECALCIFEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CORTICOSTEROID; CYCLOSPORIN; ESTROGEN; ETIDRONIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; TACROLIMUS; TAMOXIFEN; TUMS; UNCLASSIFIED DRUG; VIACTIV SOFT; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ACHLORHYDRIA; ALCOHOL CONSUMPTION; ARTHRALGIA; BEDTIME DOSAGE; BLOATING; BODY WEIGHT; BONE CANCER; BONE DENSITY; BREAST CANCER; CALCIUM INTAKE; CALCIUM OXALATE STONE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEMENTIA; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DRY NOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EPISTAXIS; EROSIVE GASTRITIS; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS INJURY; ESOPHAGUS ULCER; ESTROGEN DEFICIENCY; EYE INFLAMMATION; FLATULENCE; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERCALCEMIA; INJECTION SITE REACTION; JAW OSTEONECROSIS; KINESIOTHERAPY; LEG CRAMP; LIFESTYLE MODIFICATION; LOADING DRUG DOSE; METASTASIS; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NASAL PRURITUS; NAUSEA; NOSE CONGESTION; OSTEOLYSIS; OSTEOPENIA; PARENTERAL NUTRITION; PHYSICAL ACTIVITY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SMOKING; SPINE FRACTURE; STROKE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; ULTRASOUND; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; WRIST FRACTURE; FEMALE; FRACTURE; HEALTH CARE COST; METHODOLOGY; QUALITY OF LIFE; RADIODENSITOMETRY; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; CALCIUM, DIETARY; DENSITOMETRY, X-RAY; FEMALE; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME; VITAMIN D;

EID: 34347253249     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426507022003276     Document Type: Review

References (50)

1. National Osteoporosis Foundation. Osteoporosis disease statistics: "fast facts." Available at: http://www.nof.org/osteoporosis/ diseasefacts.htm. Accessed November 25, 2006.
2. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141.
3. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77:453-468.
4. North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause. 2002;9:84-101.
5. Zuckerman JD. Hip fracture. N Engl J Med. 1996;334:1519-1525.
6. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003:38.
7. Adachi JD, Loannidis G, Berger C, et al. The influence of osteoporotic fractures on health-related quality of life in communitydwelling men and women across Canada. Osteoporos Int. 2001;12:903-908.
8. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LF 3rd. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137:1001-1005.
9. Greendale GA, Barrett-Conner E, Ingles S, Haile R. Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. J Am Geriatr Soc. 1995;43:955-961.
10. National Osteoporosis Foundation, American Academy of Orthopaedic Surgeons. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 1998:30.
11. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929-1936.
12. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006;81:662-672.
13. rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721-739.
14. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323.
15. Melton LJ 3rd, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL. Vertebral fractures predict subsequent fractures. Osteoporos Int. 1999;10:214-221.
16. Miller PD, Zapalowski C, Kulak CA, Bilezikian JP. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab. 1999;84:1867-1871.
17. Raisz LG. Clinical practice: screening for osteoporosis. N Engl J Med. 2005;353:164-171.
18. Rosen CJ. Clinical practice: postmenopausal osteoporosis. N Engl J Med. 2005;353:595-603.
19. Leib ES, Lewiecki EM, Binkley N, Hamdy RC; International Society of Clinical Densitometry. Official positions of the International Society for Clinical Densitometry. J Clin Densitom. 2004;7:1-6.
20. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J; Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis: Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000;11(suppl 6):S2-S17.
21. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY Study. J Bone Miner Res. 2000;15:1526-1536.
22. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int. 2000;11:281-294.
23. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:544-564.
24. United States Public Health Service, Office of the Surgeon General. Bone health and osteoporosis a report of the surgeon general. Available at: http://purl.access.gpo.gov/GPO/LPS54866. Accessed November 25, 2006.
25. nd ed. St. Louis, MO: Mosby; 2001:107-127.
26. Marieb EN. Human Anatomy & Physiology. 4th ed. Menlo Park, CA: Benjamin/Cummings; 1998:xxiii, 1192.
27. Pray WS. Calcium supplements: benefits and risks. US Pharm. 2004;16-26.
28. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010-2018.
29. American Pharmaceutical Association. Handbook of Non-Prescription Drugs. Washington, DC: American Pharmaceutical Association; 2000:419.
30. Over-the-Counter Products & Osteoporosis: Case Discussions, National Osteoporosis Foundation: Osteoporosis Clinical Updates. 2002;3:1-7.
31. Brender E, Burke A, Glass RM. JAMA patient page: vitamin D. JAMA. 2005;294:2386-2387.
32. Hirabayashi H, Fujisaki J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin Pharmacokinet. 2003;42:1319-1330.
33. Alendronate (Fosamax) [package insert]. Whitehouse Station, NJ: Merck & Co; 2000.
34. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
35. Risedronate (Actonel) [package insert]. Cincinnati, OH: Proctor and Gamble; 2005.
36. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial: Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
37. Ibandronate (Boniva) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006.
38. Woo SB, Hetein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-761.
39. Kuehn BM. Reports of adverse events from bone drugs prompt caution. JAMA. 2006;295:2833-2836.
40. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137:1144-1150.
41. Follin SL, Hansen LB. Current approaches to the prevention and treatment of postmenopausal osteoporosis. Am J Health Syst Pharm. 2003;60:883-901.
42. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial: Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.
43. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study: PROOF Study Group. Am J Med. 2000;109:267-276.
44. Rossouw JE, Anderson G, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
45. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA. 2003;289:2525-2533.
46. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005;20:1905-1911.
47. Ettinger B, SanMartin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19:745-751.
48. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207-1215.
49. Teriparatide (Forteo) [package insert]. Indianapolis, IN: Eli Lilly & Co; 2004.
50. Bazaldua OV, Bruder J. Teriparatide (Forteo) for osteoporosis. Am Fam Physician. 2004;69:1983-1984.